The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
For Immediate Release
October 10, 2014
Release
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infecti on. It is also the first approved regimen that does not require administration with interferon or (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 10, 2014 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
For Immediate Release
October 10, 2014
Release
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - October 9, 2014 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Health Affairs October Issue: Specialty Drugs — Cost, Impact, And Value
The October issue of Health Affairs, released today, includes a number of studies looking at the high costs associated with today’s increasingly prevalent specialty drugs. Other subjects covered in the issue: an assessment of whether some hospitals may be taking advantage of the 340B drug discount program; a review of how shortened residency shifts impact patient care; a study on the increasing costs associated with Hepatitis C and advanced liver disease; and more.
The new issue will be discussed at a Washington DC briefing tomorrow. This issue of Health Affairs was supported by CVS Health.
Do specialty drugs offer value...
Source: Health Affairs Blog - October 6, 2014 Category: Health Management Authors: Chris Fleming Tags: All Categories Biotech Consumers Health Care Costs Hospitals Pharma Physicians Source Type: blogs
The long road to a blockbuster drug
One thousand dollars per pill?
A single treatment course for hepatitis C virus to cost $83,000?
How can those prices be justified?
The drug-discovery process is a long one, fraught with disappointments and massive investment, no matter what the outcome. Some pharmaceutical companies argue that the high prices charged for their rare “blockbuster” drugs help them recover research and development costs.
Continue reading ...
Your patients are rating you online: How to respond. Manage your online reputation: A social media guide. Find out how. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - September 24, 2014 Category: Journals (General) Authors: Vern L. Schramm, PhD Tags: Meds Medications Source Type: blogs
What we are not afraid to say about Ebola virus
In a recent New York Times OpEd entitled What We’re Afraid to Say About Ebola, Michael Osterholm wonders whether Ebola virus could go airborne:
You can now get Ebola only through direct contact with bodily fluids. If certain mutations occurred, it would mean that just breathing would put one at risk of contracting Ebola. Infections could spread quickly to every part of the globe, as the H1N1 influenza virus did in 2009, after its birth in Mexico.
Is there any truth to what Osterholm is saying?
Let’s start with his discussion of Ebola virus mutation:
But viruses like Ebola are notoriously sloppy in replicating, me...
Source: virology blog - September 19, 2014 Category: Virology Authors: Vincent Racaniello Tags: Basic virology Information aerosol transmission airborne transmission ebola virus evolution hemorrhagic fever Michael Osterholm mutation viral Source Type: blogs
